Skip to main content
. 2021 Dec 8;8:1579–1596. doi: 10.2147/JHC.S327339

Figure 7.

Figure 7

Changes in exosome-derived glypican 3 (eGPC3) and CD9 (eCD9) in response to tumor-directed therapy for hepatocellular carcinoma (HCC). (A) Affinity capture ELISA optical density (OD) for eGPC3 before and after doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) in patients responding to therapy. (B) OD for eCD9 in patients responding to treatment. (C) Serum AFP levels in treatment responsive patients. (D) OD for eGPC3 in patients who did not respond to DEB-TACE. (E) OD for eCD9 in treatment non-responders. (F) Serum AFP levels in treatment non-responders. (G) Receiver operating characteristic (ROC) curve plots for decrease in eCD9 content compared to AFP decrease post-treatment for response to treatment. (H) ROC curve plot of in eGPC3 compared to increase in AFP for non-response to treatment. Data indicate mean ± standard error of mean and analyzed by paired t-test. P values were displayed as nsP > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001.